Qiagen Increases Offer Price for Cellestis Acquisition | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen has increased the offering price for its proposed acquisition of Australian biotech firm Cellestis.

The offering price has been increased from A$3.55 (US$3.79) per share to A$3.80 per share, under the terms of an amended proposal. The transaction value for the deal has increased to US$374 million from US$355 million, Qiagen said Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.